Clinical and Economic Impact of Hybrid Closed-Loop Systems for T1 Diabetes Management in Spain
Authors' conclusion
HCL systems should be considered the primary treatment option compared with is-CGM+CSII therapy for people with type 1 diabetes mellitus in Spain.
Study context
- Population
- Simulated cohort of people with T1D, characteristics from published literature, Spainsimulated cohort
- Participants
- 1,000 participants
- Comparison
- Hybrid closed-loop (HCL) vs intermittently scanned continuous glucose monitoring (is-CGM)+continuous subcutaneous insulin infusion (CSII)
- Outcome
- Clinical and economic outcomes
- Follow-up
- 50 years
Methodological detailsIQVIA Core Diabetes Model v10.0 simulation, Spanish health care system perspective, time horizons 5, 15, 30 and 50 years
- IQVIA Core Diabetes Model v10.0 simulation
- Spanish health care system perspective
- Time horizons 5, 15, 30 and 50 years
Main finding
As reported in the abstract
Incremental QALYs gained with HCL at 50 years
1.15
Cost savings at 50 years (highest), mostly from lower amputation, ulcer and nephrological event rates
28 704 922€/1000 individuals
Original publication
Clinical and Economic Impact of Hybrid Closed-Loop Systems for T1 Diabetes Management in Spain. Endocr Pract. Published 6 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →